These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23880800)

  • 1. Rituximab in the treatment of nephrotic syndrome: a systematic review.
    Otukesh H; Hoseini R; Rahimzadeh N; Fazel M
    Iran J Kidney Dis; 2013 Jul; 7(4):249-56. PubMed ID: 23880800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
    Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is rituximab effective in childhood nephrotic syndrome? Yes and no.
    Kemper MJ; Lehnhardt A; Zawischa A; Oh J
    Pediatr Nephrol; 2014 Aug; 29(8):1305-11. PubMed ID: 23820888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
    Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
    Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
    Kamei K; Ishikura K; Sako M; Ito S; Nozu K; Iijima K
    Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for nephrotic syndrome in children.
    Iijima K; Sako M; Nozu K
    Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab can induce remission of nephrotic syndrome in the absence of peripheral B-cells.
    Rood IM; Huussen J; Wetzels JF; Deegens JK
    Nephrology (Carlton); 2015 Sep; 20(9):667-8. PubMed ID: 26278122
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
    Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
    Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
    Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome.
    Hoseini R; Sabzian K; Otukesh H; Zafaranloo N; Panahi P; Rahimzadeh N; Nakhaie S; Akhavan Sepehi M
    Iran J Kidney Dis; 2018 Jan; 12(1):27-32. PubMed ID: 29421774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
    Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
    Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
    Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The uncertainty of rituximab and steroid dosing in refractory steroid-resistant nephrotic syndrome.
    Hirano D; Fujinaga S; Nishizaki N
    Clin Nephrol; 2012 Jun; 77(6):510-2. PubMed ID: 22595396
    [No Abstract]   [Full Text] [Related]  

  • 19. Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?
    Fujinaga S; Mizutani A
    Clin Exp Nephrol; 2020 Dec; 24(12):1187-1188. PubMed ID: 32728924
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.